Pacira updates Q1 guidance


Pacira Pharmaceuticals' (PCRX -1.1%) EXPAREL will deliver ~$34.4M net sales in Q1 according to an 8-K published today.

Quick assets were $64.6M as of March 31.

Consensus estimates for Q1 and Q2 are a loss of $0.31/share on revenues of $34.3M and a loss of $0.17/share on revenues of $40.9M, respectively.

Estimates for 2014 and 2015 are a loss of $0.35/share on revenues of $172.1M and earnings of $2.25 on revenues of $306.6M, respectively.

280 mutual funds have positions, up from 227 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs